Table 2 The relationship between RNA m6A methylation and Clinical features in breast cancer patient
From: The emerging role of RNA N6-methyladenosine methylation in breast cancer
Types | Component | Regulation | Sources | Clinicopathological features and prognosis | Ref. |
|---|---|---|---|---|---|
Writers | MELLT3 | Up-regulation | Normal and Luminal subtypes | MELLT3 associate with worse prognosis. | [23] |
Down | TNBC | MELLT3 associate with better DMFS and OS. | |||
WTAP | Down | Breast | Reduced of METTL14 have poor DMFS. | [26] | |
METTL14 | Up-regulation | Normal, Luminal subtypes | 1.Reduced of METTL14 have poor DMFS. 2.METTL14 associate with T staging, without molecular Typing, microvascular invasion, nerve invasion and metastasis. | [26] | |
KIAA1429 | Down | HER2+ subtype | KIAA1429 associate with intrinsic subclasses, nodal metastasis, and worse OS. | [32] | |
CBLL1 | Up-regulation | Breast cancer | CBLL1 associate with ER status. | [34] | |
ZC3H13 | Down | TNBC | Have no association with OS | [87] | |
Erasers | FTO | Up-regulation | HER2+, Normal, Luminal subtypes, Invasive ductal carcinoma. | 1.FTO associate with advanced progression, peritumoral lymphovascular invasion, lymph node metastasis, TNM stage, HER2 status and ER/PR status. 2.FTO associate with shorter DFS/OS/RFS. | |
ALKBH5 | Up-regulation | Breast cancer | ALKBH5 have no association with DMFS. | [26] | |
Readers | YTHDF1 YTHDF2 YTHDF3 | Up-regulation | Breast cancer | 1.YTHDF1 associate worse OS and RFS 2.YTHDF2 associate brain metastasis 3.YTHDF3 associate with worse OS and RFS | |
FMR1 | Up-regulation | Breast cancer | FMR1 associate with high tumor grade (G3) and high Ki67 and easier metastasis to the lungs | [42] | |
FXR1 | Up-regulation | TNBC | FXR1 associate with worse pCR and poor DFMS and OS. | ||
HNRNPA2B1 | Up-regulation | Breast cancer | 1.Have correlation with endocrine resistance. 2.Associated with worse prognosis | [41] | |
Down | Breast Cancer | Associated with better OS. | [90] | ||
IGF2BP1 | Up-regulation | Breast cancer | IGF2BP1 does not affect tumor growth or size. | [55] | |
IGF2BP2 | Up-regulation | Breast cancer | IGF2BP2 correlate with advanced stage and poor survival. | ||
IGF2BP3 | Up-regulation | TNBC | 1.IGF2BP3 associate with larger size, higher grade, higher clinical stage, necrosis, CK5/6. 2. IGF2BP with worse DFS/OS. 3.IGF2BP3 promote chemoresistance to doxorubicin and mitoxantrone. | ||
G3BP1 | Up-regulation | Breast cancer | G3BP1 associate with tumor response to the Akt-inhibitor MK-2206. | [82] |